Verve ’s stock tumbles as biotech pauses gene editing trial over safety concerns
Verve Therapeutics is pausing enrollment in its lead gene editing medicine and sharing its next steps.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Hannah Green Source Type: news